CN115226390B - 使用细胞色素p450的抑制剂增强3-((甲基磺酰基)氨基)-2-(((4-苯基环己基)氧基)甲基)哌啶-1-羧酸甲酯或其盐的药代动力学或增加其血浆浓度的方法 - Google Patents

使用细胞色素p450的抑制剂增强3-((甲基磺酰基)氨基)-2-(((4-苯基环己基)氧基)甲基)哌啶-1-羧酸甲酯或其盐的药代动力学或增加其血浆浓度的方法

Info

Publication number
CN115226390B
CN115226390B CN202180017795.5A CN202180017795A CN115226390B CN 115226390 B CN115226390 B CN 115226390B CN 202180017795 A CN202180017795 A CN 202180017795A CN 115226390 B CN115226390 B CN 115226390B
Authority
CN
China
Prior art keywords
compound
reducing
metabolism
methyl
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180017795.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN115226390A (zh
Inventor
M·罗格
H·费斯勒
卢弘
K·文卡克里希南
张立明
J·瓦格纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CN115226390A publication Critical patent/CN115226390A/zh
Application granted granted Critical
Publication of CN115226390B publication Critical patent/CN115226390B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180017795.5A 2020-01-10 2021-01-07 使用细胞色素p450的抑制剂增强3-((甲基磺酰基)氨基)-2-(((4-苯基环己基)氧基)甲基)哌啶-1-羧酸甲酯或其盐的药代动力学或增加其血浆浓度的方法 Active CN115226390B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062959514P 2020-01-10 2020-01-10
US62/959,514 2020-01-10
PCT/US2021/012447 WO2021142083A1 (en) 2020-01-10 2021-01-07 A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome p450

Publications (2)

Publication Number Publication Date
CN115226390A CN115226390A (zh) 2022-10-21
CN115226390B true CN115226390B (zh) 2026-03-20

Family

ID=74418549

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180017795.5A Active CN115226390B (zh) 2020-01-10 2021-01-07 使用细胞色素p450的抑制剂增强3-((甲基磺酰基)氨基)-2-(((4-苯基环己基)氧基)甲基)哌啶-1-羧酸甲酯或其盐的药代动力学或增加其血浆浓度的方法

Country Status (10)

Country Link
US (1) US12594269B2 (enExample)
EP (1) EP4087534A1 (enExample)
JP (1) JP7728264B2 (enExample)
KR (1) KR20220127245A (enExample)
CN (1) CN115226390B (enExample)
AU (1) AU2021205892B2 (enExample)
BR (1) BR112022013547A2 (enExample)
CA (1) CA3167050A1 (enExample)
MX (1) MX2022008392A (enExample)
WO (1) WO2021142083A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020394444B2 (en) 2019-11-25 2025-05-29 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
CN119968355A (zh) 2022-10-07 2025-05-09 橘生药品工业株式会社 环戊烷化合物
KR20250085056A (ko) 2023-12-05 2025-06-12 안희태 국궁 과녁에서 영역 구분 센서의 구성 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017135306A1 (en) * 2016-02-04 2017-08-10 Takeda Pharmaceutical Company Limited Substituted piperidine compound and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1317270A1 (en) * 2000-09-08 2003-06-11 Pharmacia Italia S.p.A. Exemestane for the treatment of oestrogen-dependent cancers
EP2968341A4 (en) 2013-03-14 2016-11-23 Pharmacyclics Llc COMBINATIONS OF BURTON TYROSINE KINASE INHIBITORS AND CYP3A4 INHIBITORS
JP6764017B2 (ja) 2016-08-04 2020-09-30 ギリアード サイエンシーズ， インコーポレイテッド がんの処置での使用のためのコビシスタット
KR20220062361A (ko) 2019-09-13 2022-05-16 다케다 야쿠힌 고교 가부시키가이샤 과도한 졸림의 치료를 위한 오렉신 2 수용체 효능제의 용도
US20220339143A1 (en) 2019-09-13 2022-10-27 Takeda Pharmaceutical Company Limited Tak-925 for use in treating narcolepsy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017135306A1 (en) * 2016-02-04 2017-08-10 Takeda Pharmaceutical Company Limited Substituted piperidine compound and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies;Boof M L, Alatrach A, Ufer M, et al.;European Journal of Clinical Pharmacology;20181004;第75卷;摘要、结论部分 *

Also Published As

Publication number Publication date
CA3167050A1 (en) 2021-07-15
BR112022013547A2 (pt) 2022-09-06
MX2022008392A (es) 2022-08-08
AU2021205892A1 (en) 2022-08-18
CN115226390A (zh) 2022-10-21
US12594269B2 (en) 2026-04-07
KR20220127245A (ko) 2022-09-19
EP4087534A1 (en) 2022-11-16
WO2021142083A1 (en) 2021-07-15
JP7728264B2 (ja) 2025-08-22
AU2021205892B2 (en) 2026-04-23
JP2023510332A (ja) 2023-03-13
US20230029486A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
JP7728264B2 (ja) シトクロムｐ４５０の阻害剤を用いて３－（（メチルスルホニル）アミノ）－２－（（（４－フェニルシクロヘキシル）オキシ）メチル）ピペリジン－１－カルボン酸メチルまたはその塩の薬物動態を改善するまたは血漿中濃度を上昇させる方法
Schröder et al. Depression and obstructive sleep apnea (OSA)
Minoguchi et al. Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast
Le Bon et al. Sleep in detoxified alcoholics: impairment of most standard sleep parameters and increased risk for sleep apnea, but not for myoclonias--a controlled study.
US20210196669A1 (en) Cannabis-based compositions for the treatment of autistic spectrum disorders
Wiegand et al. Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma
TW202131910A (zh) 使用mtorc1調節劑的治療方法
KR20120050512A (ko) 탈수초를 갖는 환자에서 ４-아미노피리딘을 사용한 지속적 치료
JP2010534628A (ja) 神経変性障害を治療するためのネラメキサンの新規組合せ
Walsh et al. Treatment of elderly primary insomnia patients with EVT 201 improves sleep initiation, sleep maintenance, and daytime sleepiness
Thomson et al. The impact of acetazolamide and dronabinol on the physiological endotypes responsible for obstructive sleep apnea
US20240148708A1 (en) Method of treating amyotrophic lateral sclerosis with pridopidine
CN1395487A (zh) 米氮平用于治疗睡眠障碍的用途
US20230190724A1 (en) Method of treating amyotrophic lateral sclerosis with pridopidine
RU2834228C1 (ru) Способ улучшения фармокинетики или повышения концентрации в плазме метил-3-((метилсульфонил)амино)-2-(((4-фенилциклогексил)окси)метил)пиперидин-1-карбоксилата или его соли с помощью ингибитора цитохрома p450
Fukutome et al. Effects of continuous positive air pressure on intraocular pressure in patients with obstructive sleep apnea during the split-night study: An open-label randomized controlled trial
KR101961368B1 (ko) 수면 무호흡 치료용 술티암
D'Souza et al. Side effects of opioid analgesics and opioid antagonists
Rutherford et al. Intravenous administration of nicotinamide adenine dinucleotide alleviates tremors associated with Parkinson’s disease: a case report
US20090054412A1 (en) Treatment of Sleep Disorders
von Leupoldt et al. The influence of corticosteroids on the perception of dyspnea in asthma
CN114096251A (zh) 用于治疗睡眠问题的莱博雷生
Beitinger et al. Long-term effects of antidepressants on sleep
Xiaowen et al. Observational study on the application of remazolam toluenesulfonate and propofol in abortion
Tay et al. A Prospective Study of Inpatient Ketamine Subanaesthetic Dose Infusion in Chronic Refractory Pain

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant